Apriori Bio is a developer of artificial intelligence prediction virus mutation system. Based on its unique artificial intelligence platform, it infers all possible mutations of the virus, and develops antibodies or drugs that can resist rapidly mutating viruses, such as new coronavirus, influenza virus and human immunity. Defective virus. Recently, Flagship Pioneering announced the launch and $50 million in funding from Apriori Bio, a biotech startup developing treatments for infectious diseases.
This article is reproduced from: https://www.itjuzi.com/investevent/13341644
This site is for inclusion only, and the copyright belongs to the original author.